Deutsch
English
Русский

Universitätsklinikum Würzburg 

ZIM (Zentrum Innere Medizin)
Haus A3/A4 

Oberdürrbacherstr. 6

97080 Würzburg

ZOM / ZIM

Publikationen 2015

Heidrich B, Cordes HJ, Klinker H, Moller B, Naumann U, Rossle M, Kraus MR, Boker KH, Roggel C, Schuchmann M, Stoehr A, Trein A, Hardtke S, Gonnermann A, Koch A, Wedemeyer H, Manns MP, Cornberg M

Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial.

PloS one 2015; 10: e0128069
Impact Factor: 3,057

 

Heinz WJ, Cabanillas Stanchi KM, Klinker H, Blume O, Feucht J, Hartmann U, Feuchtinger T, Lang P, Handgretinger R, Doring M

Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation

Medical mycology 2015; Oct 18. pii: myv087. [Epub ahead of print]
Impact Factor: 2,644

 

Hecht M, Erber S, Harrer T, Klinker H, Roth T, Parsch H, Fiebig N, Fietkau R, Distel LV

Efavirenz Has the Highest Anti-Proliferative Effect of Non-Nucleoside Reverse Transcriptase Inhibitors against Pancreatic Cancer Cells

PLoS One 2015; 10: e0130277
Impact Factor: 3,057

 

Lee M, Eyer F, Felgenhauer N, Klinker HH, Spinner CD

Overdose of dolutegravir in combination with tenofovir disaproxil fumarate/emtricitabine in suicide attempt in a 21-year old patient

AIDS Res Ther 2015; 12:18. doi: 10.1186/s12981-015-0054-y
Impact Factor: 1,414

 

Kunisaki KM, Niewoehner DE, Collins G, Nixon DE, Tedaldi E, Akolo C, Kityo C, Klinker H, La Rosa A, Connett JE; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group

Pulmonary function in an international sample of HIV-positive, treatment-naïve adults with CD4 counts > 500 cells/μL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.

HIV Med 2015; 16 Suppl 1:119-28
Impact Factor: 3,341

 

Spinner CD, Wille F, Schwerdtfeger C, Thies P, Tanase U, Von Figura G, Schmid RM, Heinz WJ, Klinker HH

(2015) Pharmacokinetics of chewed vs. swallowed raltegravir in a patient with AIDS and MAI infection: some new conflicting data

AIDS research and therapy 2015; 12: 1
Impact Factor: 1,414

 

Heinz WJ, D. Kuschak, D. Schirmer, A. Grau, D. Keller, H. Klinker

HPLC-Method for the determination of the S- and R-diastereomers of telaprevir in patients with treatment of hepatitis C

J LAB Med 2015; DOI 10.1515/labmed-2015-001, 1-6

 

Kroiss M, Plonné D, Kendl S, Schirmer D, Ronchi CL, Schirbel A, Zink M, Lapa C, Klinker H, Fassnacht M, Heinz W, Sbiera S.

Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma.

Eur J Endocrinol. 2015 Dec 15. pii: EJE-15-0946. [Epub ahead of print]
Impact Factor: 3,892

 

INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.

N Engl J Med. 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20
Impact Factor: 59,558

 

Boch T, Reinwald M, Postina P, Cornely OA, Vehreschild JJ, Heußel CP, Heinz WJ, Hoenigl M, Eigl S, Lehrnbecher T, Hahn J, Claus B, Lauten M, Egerer G, Müller MC, Will S, Merker N, Hofmann WK, Buchheidt D, Spiess B

Identification of invasive fungal diseases in immunocompromised patients by combining an Aspergillus specific PCR with a multifungal DNA-microarray from primary clinical samples.

Mycoses. 2015 Dec;58(12):735-45. doi: 10.1111/myc.12424. Epub 2015 Oct 26.
Impact Factor: 2,332

 

White PL, Barnes RA, Springer J, Klingspor L, Cuenca-Estrella M, Morton CO, Lagrou K, Bretagne S, Melchers WJ, Mengoli C, Donnelly JP, Heinz WJ, Loeffler J; EAPCRI.

Clinical Performance of Aspergillus PCR for Testing Serum and Plasma: a Study by the European Aspergillus PCR Initiative.

J Clin Microbiol. 2015 Sep;53(9):2832-7. doi: 10.1128/JCM.00905-15. Epub 2015 Jun 17
Impact Factor: 3,631

 

Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, Cornely OA, Heinz WJ, Jagannatha S, Koh LP, Kontoyiannis DP, Lee DG, Nucci M, Pappas PG, Slavin MA, Queiroz-Telles F, Selleslag D, Walsh TJ, Wingard JR, Maertens JA.

Combination antifungal therapy for invasive aspergillosis: a randomized trial.

Ann Intern Med. 2015 Jan 20;162(2):81-9. doi: 10.7326/M13-2508
Impact Factor: 16,593

 

H. Klinker

TDM – wann heute noch sinnvoll?

6. Münchener AIDS und Hepatitis Werkstatt, 13.-14.3.2015, Kongressband S. 27-28, ISBN 978-3-9817252-0-9

 

T. M. Welzel, K. Herzer, P. Ferenci, J. Petersen, M. Gschawantler, M. Cornberg, T. Berg, U. Spengler, O. Weiland, M. Van der Valk, H. Klinker, J. Rockstroh, P. Ingiliz, M. Peck-Radosavljevic, M. J. Jimenez-Exposito, S. Zeuzem

Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: preliminary results of a multicenter compassionate use program (HERACLES cohort)

50th Annual Meeting of the European Association for the Study of the Liver (EASL), Wien, 22.-26.4.2015, Abstract P0772, J Hepatol 2015; 62 (Suppl 2): S619-620

 

V. Knop, E. Herrmann, J. Vermehren, J. Petersen, P. Buggisch, H. Wedemeyer, M. Cornberg, S, Mauss, M. Sprinzl, T. Berg, F. van Bömmel, H. Klinker, D. Hüppe, M. Rausch, T. Welzel, A. Vermehren, S. Susser, S. Zeuzem, C. Sarrazin.

Prediction of HBsAg seroclearance and HBsAg seroconversion in a cohort of inactive European hepatitis B (HBV) carriers: a prospective longitudinal study (ALBATROS study)

50th Annual Meeting of the European Association for the Study of the Liver (EASL), Wien, 22.-26.4.2015, Abstract P0581, J Hepatol 2015; 62 (Suppl 2): S533-534

 

Heinz W., A. Grau, H. Klinker

Casphylax-pilot - a prospective trial to evaluate safety and efficacy of intermittent application of increased doses of Caspofungin for antifungal prophylaxis in high risk patients. Poster 3920

ECCMID 4.2015, Kopenhagen

 

W. J. Heinz, A. Grau, H. Klinker

Pharmacokinetics of increased doses of caspofungin in an intermittent, three times weekly, dosing regimen

ISHAM 4.-8.5.15, Poster, Melbourne

 

H. Klinker

Brauchen wir neue Marker? Und was brauchen wir nicht mehr? TDM- wann heute noch sinnvoll?

Connexi 2015, 3; 2: 47-49, Mai 2015

 

S. P. Zvada, S. Sy, N. Bauer, M. von Bibra, D. Clemens, H. Klinker, H. Derendorf, B. Rosenkranz

Pharmacokinetics of Efavirenz Among HIV infected South Africans Across Different Age Groups Including Pregnant Women

PAGE (Population Approach group Europe) Meeting 2015, 2.-5.6.2015, Heronissos, Crete, Greece, Abstract II-77

 

W. Heinz, D. Schirmer, D. Kuschak, H. Klinker

Determination of dolutegravir serum concentrations in daily clinical practice using a new HPLC method

7. Deutsch-Österreichischer AIDS-Kongress, Düsseldorf 24.-27.06.2015, Poster PW 55

Posterpreis

 

J. Zirkel, H. Klinker, W. Heinz

Innovativge Therapie des Morbus Castleman bei einem HIV-positiven Patienten mit IL6- und CD20-Antikörpern

7. Deutsch-Österreichischer AIDS-Kongress, Düsseldorf 24.-27.06.2015, Poster PW 95

 

C. Kasang, S. Kalluvya, C. Majinge, M. Mlewa, I. Massawe, R. Kabyemera, K. Magambo, A. Ulmer, H. Klinker, E. Gschmack, A. Horn, E. Koutsilieri, W. Preiser, D. Hofmann, A. Müller, B. Weissbrich, A. Rethwilm, A. Stich, C. Scheller

Low-dose prednisolone attenuates disease progression in antiretroviral-untreated HIV-infection: sex-based differences

7. Deutsch-Österreichischer AIDS-Kongress, Düsseldorf 24.-27.06.2015, Poster PW 124

 

S. Wiebecke, M. Schuhmann, H. Klinker, W. Heinz

TDM-gesteuerte kombinierte antiretrovirale und tuberkulostatische Therapie bei Kurzdarmsyndrom

7. Deutsch-Österreichischer AIDS-Kongress, Düsseldorf 24.-27.06.2015, Poster PW 130

 

H. Klinker

HCV-HIV-Koinfektion: Große Fortschritte dank neuer Substanzen

MMW Fortschr Med. 2015 Jun;157 Suppl 2:36-40. doi: 10.1007/s15006-015-3165-4

 

H. Klinker

Interaktionen mit HCV-DAA – was ist klinisch relevant?

Hepatitis & More 1/2015; 12-21

 

H. Klinker

HIV-HCV-Koinfektion: Große Fortschritte dank neuer Substanzen

Ärzte Woche, Springer Medizin.at, 20.8.2015, 14-15, Österreich

 

Knop V, Herrmann E, Vermehren J, Petersen J, Buggisch P, Wedemeyer H, Cornberg M, Mauss S, Sprinzl M, Berg T, van Bömmel F, Klinker H, Hüppe D, Rausch M, Welzel T, Vermehren A, Susser S, Zeuzem S, Sarrazin C

Prädiktion von HBsAg Verlust und HBsAg Serokonversion bei Patienten mit niedrig-replikativer chronischer Hepatitis B (HBV) – Infektion: 2 Jahres-Daten einer deutschen prospektiven longitudinalen Studie (ALBATROS Studie)

70. Jahrestagung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten, 16.-19.09.2015, Leipzig, KG 134, Z Gastroenterol 2015; 53: 897

 

G. Fätkenheuer, W. Kern, H. Klinker

Therapiealternativen – Wenn Antibiotika knapp werden

Deutsches Ärzteblatt 2015; 112 (40): A 1622

 

H. Klinker

Drug-Drug-Interactions with new HCV-DAAs

17. Jahreskongress für Klinische Pharmakologie, Köln, 1.-2-10.2015, Abstract 02, German Medical Science GMS Publishing House; 2015. Doc15vklipha02

www.egms.de/static/en/meetings/vklipha2015/15vklipha02.shtml

 

S. P. Zvada, S. Sy, D. Fouche, H. Klinker, H. Derendorf, B. Rosenkranz

Fluconazole had no effect on the population pharmacokinetics of efavirenz, nevirapine and ritonavir-boosted lopinavir in treatment experienced south Africans.

Pharmakologie Jahrestagung Johannesburg/WITS Congress 31.8.-2.9.15

 

T. M. Welzel, K. Herzer, P. Ferenci, J. Petersen, M. Gschwantler, M. Cornberg, T. Berg, U. Spengler, O. Weiland, M. Van der Valk, H. Klinker, J. Rockstroh, P. Ingiliz, M. Peck-Radosavljevic, M. J. Jimenez-Exposito, S. Zeuzem

Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: interim results of a multicenter compassionate use program.

The Viral Hepatitis Congress 2015 Sep 10-12, 2015, Frankfurt, Germany

 

Jürgen Rockstroh, Lars Peters ; Ellen Tedaldi; Andrew Phillips; Brian Edlin; Sebastien Gallien; Klinker, Hartwig ; Pavlos Kokordelis, Mocroft, Amanda; Grint, Daniel

The natural history of HCV-RNA among HIV/HCV coinfected individuals in the ESPRIT study; documented spontaneous clearance in 9 individuals with CC and CT IL28B genotypes

15th European AIDS Conference (EACS), 21. – 24.10.2015, Barcelona, Poster 13/20

 

K. M. Kunisaki, D. E. Niewoehner, G. Colins, D. E. Nixon, E. Tedaldi, C. Akolo, C. Kityo, H. Klinker, A. La Rosa, J. Vestbo, J. E. Connett, for the INSIGHT START Pulmonary Substudy Group

Lung function decline in HIV: Effects of immediate versus deferred ART treatment on lung function decline in a multi-site, international, randomized controlled trial.

15th European AIDS Conference (EACS), 21. – 24.10.2015, Barcelona, Poster

 

J. Rockstroh, T. M. Welzel, P. Ingiliz, J. Petersen, M. Van der Valk, K. Herzer, P. Ferenci, M. Gschwantler, M. Cornberg, T. Berg, U. Spengler, O. Weiland, H. Klinker,  M. Peck-Radosavljevic, Y. Zhao, M. J. Jimenez Exposito, S. Zeuzem.

Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients coinfected with HIV: interim results of a multicenter compassionate use program.

66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 13. - 17.11.2015, San Francisco, Abstract 1058, Hepatology 2015; 62 (Suppl): 728A

 

K. Herzer, T. M. Welzel, P. Ferenci, J. Petersen, M. Gschwantler, M. Cornberg, T. Berg, U. Spengler, O. Weiland, M. Van der Valk, H. Klinker, J. Rockstroh, E. Schott, M. Peck-Radosavljevic, Y. Zhao, M. J. Jimenez Exposito, S. Zeuzem.

Daclatasvir plus sofosbuvir with or without ribavirin is safe and efficious in liver transplant recipients with HCV recurrence: interim results of a multicenter compassionate use program.

66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 13. - 17.11.2015, San Francisco, Abstract 252, Hepatology 2015; 62 (Suppl): 341A

 

L. Sommer, K. H. Peiffer, J. Dietz, S. Susser, J. Petersen, P. Buggisch, M. Cornberg, S. Mauss, H. Klinker, M. F. Sprinzl, F. van Bömmel, E. Hildt, C. Berkowski, D. Perner, S. Passmann, S. Zeuzem, C. Sarrazin.

Genotype-Specific Prevalence and Importance of Naturally Occurring Precore-, Basal Core Promoter- and preS-Mutations in a Large European Study Cohort of Patients Chronically Infected with Hepatitis B Virus.

66th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), 13. - 17.11.2015, San Francisco, Abstract 1559, Hepatology 2015; 62 (Suppl): 971A